-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
BriaCell Therapeutics (CVE:BCT) Trading Down 3.8%
BriaCell Therapeutics (CVE:BCT) Trading Down 3.8%
BriaCell Therapeutics Corp. (CVE:BCT – Get Rating)'s stock price fell 3.8% during trading on Friday . The company traded as low as C$10.60 and last traded at C$10.60. 3,402 shares were traded during mid-day trading, a decline of 73% from the average session volume of 12,671 shares. The stock had previously closed at C$11.02.
BriaCell Therapeutics Stock Down 3.8 %
The firm has a market capitalization of C$168.68 million and a PE ratio of -28.19. The business's 50 day simple moving average is C$10.60 and its 200 day simple moving average is C$10.60. The company has a current ratio of 129.63, a quick ratio of 128.68 and a debt-to-equity ratio of 0.05.
Get BriaCell Therapeutics alerts:Insider Transactions at BriaCell Therapeutics
In other news, Director William Williams bought 27,272 shares of the stock in a transaction dated Thursday, July 14th. The stock was purchased at an average price of C$3.58 per share, for a total transaction of C$97,497.40. Following the acquisition, the director now owns 27,272 shares of the company's stock, valued at C$97,497.40.
About BriaCell Therapeutics
(Get Rating)BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing approaches for the management of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, an off-the-shelf personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test.
Further Reading
- Institutional Buying Put A Bottom In Marvell Technology
- Dell Stock Retreats On Weaker Sales, Falls Into Value Terrirtory
- 3 Reasons Dollar General's Rally Has Legs
- Salesforce Stock Could Have Long Term Potential After Earnings
- Should AbbVie Inc. Have a Place in Your Dividend Portfolio?
Receive News & Ratings for BriaCell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BriaCell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
BriaCell Therapeutics Corp. (CVE:BCT – Get Rating)'s stock price fell 3.8% during trading on Friday . The company traded as low as C$10.60 and last traded at C$10.60. 3,402 shares were traded during mid-day trading, a decline of 73% from the average session volume of 12,671 shares. The stock had previously closed at C$11.02.
BriaCell Treateutics Corp.(CVE:BCT-GET Rating)股價週五下跌3.8%。該公司股價最低跌至10.60加元,最新報10.60加元。午盤成交量為3,402股,較12,671股的平均成交量下降73%。該股此前收盤報11.02加元。
BriaCell Therapeutics Stock Down 3.8 %
Briacell治療公司股價下跌3.8%
The firm has a market capitalization of C$168.68 million and a PE ratio of -28.19. The business's 50 day simple moving average is C$10.60 and its 200 day simple moving average is C$10.60. The company has a current ratio of 129.63, a quick ratio of 128.68 and a debt-to-equity ratio of 0.05.
該公司市值為1.6868億加元,市盈率為-28.19倍。該業務的50日簡單移動均線切入位在10.60加元,200日簡單移動均線切入位在10.60加元。該公司的流動比率為129.63,速動比率為128.68,債務權益比率為0.05.
Insider Transactions at BriaCell Therapeutics
Briacell治療公司的內幕交易
In other news, Director William Williams bought 27,272 shares of the stock in a transaction dated Thursday, July 14th. The stock was purchased at an average price of C$3.58 per share, for a total transaction of C$97,497.40. Following the acquisition, the director now owns 27,272 shares of the company's stock, valued at C$97,497.40.
另外,董事威廉·威廉姆斯在一筆日期為7月14日(星期四)的交易中購買了27,272股該公司股票。該股是以每股3.58加元的平均價格收購的,總交易金額為97,497.40加元。收購完成後,董事現在擁有27,272股該公司股票,價值97,497.40加元。
About BriaCell Therapeutics
Briacell治療公司簡介
BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing approaches for the management of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, an off-the-shelf personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test.
BriaCell治療公司是一家免疫腫瘤學生物技術公司,致力於開發癌症管理方法。它的主要候選者是Bria-IMT,這是一項與免疫檢查點抑制劑聯合治療乳腺癌的I/IIa期臨牀試驗。該公司還與國家癌症研究所簽訂了合作研發協議,開發針對晚期乳腺癌的現成個性化免疫療法Bria-OTS,以及診斷測試BriaDx。
Further Reading
進一步閲讀
- Institutional Buying Put A Bottom In Marvell Technology
- Dell Stock Retreats On Weaker Sales, Falls Into Value Terrirtory
- 3 Reasons Dollar General's Rally Has Legs
- Salesforce Stock Could Have Long Term Potential After Earnings
- Should AbbVie Inc. Have a Place in Your Dividend Portfolio?
- 機構買入讓Marvell科技陷入低谷
- 戴爾股票因銷售疲軟而回落,跌入可怕的價值
- Dollar General的拉力賽有三個理由
- Salesforce股票在盈利後可能具有長期潛力
- 艾伯維公司。應該在你的股息投資組合中佔有一席之地嗎?
Receive News & Ratings for BriaCell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BriaCell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受Briacell治療日報的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對BriaCell治療公司和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧